Fragility Radar delivers structural risk research that identifies market fragility in pharmaceutical, biotechnology, and broader healthcare systems before regime changes occur. The service, aimed at institutional equity analysts, hedge fund managers, family offices, and wealth managers, provides timestamped, verifiable signals with an average lead time of 16.4 days, achieving 17 confirmed calls out of 25 published predictions.
Funding
Funding not disclosed
Founders
Product
Problem
Institutional investors and analysts often discover structural weaknesses in pharmaceutical, biotechnology, and healthcare companies only after market regimes have shifted, leading to delayed reactions and missed investment opportunities.
Solution
Fragility Radar delivers a judgment‑based structural risk research platform that identifies hidden fragility factors in healthcare equities before they manifest in price movements. The framework integrates nine distinct fragility indicators into a single analytical view, applying system‑specific thresholds that are dynamically calibrated. Each signal is timestamped, publicly verifiable, and on average provides a 16.4‑day lead time ahead of market repricing. Subscribers receive an ongoing log of named fragility calls, detailed transmission drivers, and probability‑weighted loss profiles, enabling proactive portfolio adjustments. The service is offered via an annual institutional subscription, ensuring consistent access to the research pipeline without tiered pricing or upsells.
Target Audience
Primary customers are institutional healthcare equity analysts, hedge fund portfolio managers, family offices, and wealth managers with exposure to pharmaceutical, biotech, and healthcare equities.
Features
- Nine integrated fragility factors combined into a unified analytical surface
- Dynamic calibration of system‑specific structural thresholds based on 20+ years of operating experience
- Publicly timestamped, verifiable calls with an average 16.4‑day lead time
- Sector‑wide rankings and transmission lag visualizations for cross‑company comparison
- Qualitative judgment refined by quantitative discipline, delivered as a continuous log of named calls
- Coverage of pharmaceutical, biotechnology, and broader healthcare companies across multiple S&P sectors